2024-02-01 07:13:32
Ibrutinib, a Bruton’s tyrosine kinase inhibitor, and venetoclax, a BCL2 inhibitor, have distinct and complementary mechanisms of action that have shown promising results in preclinical models and early-phase studies. The combination of the two drugs has now been examined in patients with relapsed/refractory mantle cell lymphoma (MCL).
molekuul.be/AdobeStock
The primary analysis results of the phase III SYMPATICO study, a multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of the oral combination of ibrutinib and venetoclax in patients with relapsed/refractory MCL, were presented at the Congress of the American Society of Hematology (ASH) 2023 presented.
The SYMPATICO study enrolled 267 people and assigned them to either the experimental group (ibrutinib + venetoclax) or the control group (ibrutinib + placebo). The primary endpoint, progression-free survival (PFS), assessed according to the investigators’ criteria, showed a statistically significant improvement in the combination group compared to the placebo group, with a median PFS of 31.9 months versus 22.1 months (hazard ratio 0.65; p=0.0052).
To view the content you must log in or register.
#Ibrutinib #Venetoclax #RelapsedRefractory #Mantle #Cell #Lymphoma